Navigation Links
Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
Date:7/10/2008

- Acquisition of Four Clinical Stage Product Candidates Adds to Robust

Pipeline -

DALLAS, July 10 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and MacroChem Corporation (OTC Bulletin Board: MACM) announced today that they had signed a definitive merger agreement providing for Access to acquire MacroChem through the issuance of 2.5 million shares of Access Pharmaceuticals' common stock. MacroChem's product portfolio includes two clinical stage oncology products, 4-thio Ara-C, which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from the NIH and is currently partnered with Access Pharmaceuticals. MacroChem's portfolio of late stage clinical drug candidates includes Pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection that has already completed two Phase 3 clinical trials; EcoNail, a novel topical treatment for onychomycosis that is currently in a Phase 2 clinical trial. Macrochem also has two proprietary dermatology drug platforms, SEPA(R) and MacroDerm. The acquisition is expected to close in Q3 2008.

"The acquisition of MacroChem brings multiple late-stage clinical drug candidates into the Access pipeline, some of which are further along than Access' current assets," stated Jeffrey B. Davis, Access' President and CEO. "We are currently active in partnering and out-licensing discussions, and MacroChem's dermatology assets will be added to that partnering effort. The oncology assets are highly synergistic with the oncology development efforts ongoing at Access, and we look forward to the opportunity to move them along and monetize those assets through additional partnering activities."

"With the precarious state of the financial markets adding further challenges for microcap biopharmaceutical companies, we believe the strategic combination with Access is a v
'/>"/>

SOURCE Access Pharmaceuticals, Inc.; MacroChem Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
3. Concuity Announces the Launch of Its New Fully Accessible Website - Concuity.Com
4. Access Highlighted in Recent BusinessWeek Article
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care
7. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
8. Pharmasset Accesses up to $30 Million of Working Capital
9. Access Genetics Announces New Executive Appointments
10. Access Pharmaceuticals Announces $19.5 Million Recapitalization
11. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... including DESY scientists has observed tiny quantum vortices in ... the journal Science that the exotic vortices ... It is the first time that the quantum vortices, ... what is known as superfluid helium, have been detected ... says Andrey Vilesov of the University of Southern California, ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2
... and LEXINGTON, Massachusetts, August 25, 2011 Shire ... specialty biopharmaceutical company, today announced that the U.S. Food and ... (icatibant injection) for treatment of acute attacks of hereditary ... "Until now, HAE patients faced challenges gaining rapid ...
... CBI, a division of Advanstar Communications, is pleased ... Tufts Center for the Study of Drug Development and ... the keynote speaker at their Pharma/Bio Forum on Preclinical ... at the Hyatt Harborside in Boston, MA. Dr. Kaitin ...
... school science teachers will explore the nanotechnology field at ... build interest in science and engineering. ... of Engineering a $429,000 grant to fund "Innovations in ... Starting next summer, selected middle and high school ...
Cached Biology Technology:FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 2FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 3FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 4FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 5FDA Approves Shire's FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE) 6Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference 2University of Houston receives NSF grant for high school teachers program 2
(Date:8/21/2014)... involves the pancreas digesting itself resulting in severe abdominal ... UK around 20,000 patients are diagnosed with the disease ... and treatment is restricted to intravenous fluid and nutritional ... of Life Sciences, who led the research, said "The ... gall stones and excessive alcohol intake combined with a ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
(Date:8/20/2014)... Scientists from the University of Tbingen, Arizona State University, ... and Public Health Institute (Swiss TPH) isolated Mycobacterium ... at least 1000 years old. The pathogen is a ... only occasionally causes disease in humans today. These researchers ... the Peruvian coast. "The link to sea lions was ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... second most common cause of childhood blindness in the ... earlier than or at 28 weeks gestational age. The ... the retina of the eye. ROP risk increases with ... Brigham and Women,s Hospital (BWH) suggests that the antioxidant, ...
... young researchers were named Pew Scholars in the Biomedical ... join a prestigious community that includes Nobel Prize winners, ... Research Award. "During these challenging budgetary ... harder for scientists to obtain, we are proud to ...
... heavy rain, the lid of Nepenthes gracilis ... shelter on its underside directly into the fluid-filled pitcher, ... Wednesday 13 June, in the journal PLoS ONE ... a source of nutrients, enabling them to colonise nutrient-poor ...
Cached Biology News:Antioxidant shown to reduce blindness risk in extremely premature babies 222 of America's most promising scientists selected as Pew Biomedical Scholars 222 of America's most promising scientists selected as Pew Biomedical Scholars 3Pitcher plant uses rain drops to capture prey 2
... using many of the automation concepts from ... requirements are similar to those for HTS: ... 24 or 48 wells with well volumes ... the number of wells has increased to ...
... One-Step Kit is the ultimate in ... It has been specifically designed to ... Reverse-iT™ One-Step Kit combines the unique ... Thermoprime Plus DNA Polymerase to provide ...
... Immunogen: Synthetic Peptide: M(1) E F L ... P P T M D L E(19) PA1-072 ... cells.,PA1-072 has been successfully used in Western blot ... an ~86 kDa protein representing Mint3 from AtT20 ...
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
Biology Products: